Menu

California Institutes to Merge

The Scripps Research Institute will join forces with the California Institute for Biomedical Research.

Oct 25, 2016
Jef Akst

FLICKR, HÅKAN DAHLSTRÖMChemist Peter Schultz is bringing together his two nonprofit institutions—the Scripps Research Institute (TSRI) and the California Institute for Biomedical Research (Calibr)—merging them into a new biomedical research entity, according to a statement issued last week (October 20). The hope is that basic research conducted at TSRI can be fed into Calibr for preclinical and clinical development.

“The affiliation between TSRI and Calibr is the first of its kind,” Schultz, who is president of both organizations, said in the press release. “Unlike other research institutes and universities that have sought to establish translational capabilities within academic centers, we aren’t building from scratch—rather, we are integrating the strengths of two proven nonprofit organizations.”

The two institutions have collaborated since Calibr was launched in 2012, but the merge will allow them to share a board of directors as well as scientific and administrative resources, reducing overhead costs for both organizations. 

(Hat tip: Science)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.